Is the US biopharma industry headed for a turning point in 2017?
Three months ago, Brent Saunders fired a shot across the bow of the USS Big Pharma, pledging to limit Allergan’s annual price increase on its portfolio drugs to no more than single-digit percentage hikes each year. On Monday, the new US president of diabetes specialist Novo Nordisk took that pledge. And 2017 is shaping up as a potential turning point in the heated public argument over drug prices in the US.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.